Stay updated on Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors
Sign up to get notified when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.

Latest updates to the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.5%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check32 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check75 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a Phase 2 clinical trial for nab-sirolimus, which included detailed eligibility criteria and treatment protocols for patients with malignant solid tumors. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference27%
Stay in the know with updates to Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors
Enter your email address, and we'll notify you when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.